Showing results for "Treatment" in Science

With science now recognizing animal consciousness, intelligence, emotion and even morality, there must come an awareness of our own moral responsibilities towards other beings. But there's another reason to consider animals' well-being-because it is intertwined with our own. In Survival at Stake...

Seed treatments are the core of any successful crop. So much has to go right to maximize seeds’ potential and minimize threats. Young plants face pressure from their environment, insects, and several enemies that go unseen by the average eye. Listen to industry experts explore the history, present day and future of agricultural insurance, seed treatments.

The world is better when its people are connected. The ECTRIMS Podcast aims to be a sounding board for MS experts & advocates to discuss innovative work in MS research, treatment and care with the greater MS research community, while offering a collaborative platform for MS and healthcare experts to promote & nurture the advancement of research.

Justice To Healing is a podcast presented by the National Treatment Court Resource Center (NTCRC) and hosted by NTCRC co-directors Kristen DeVall, Ph.D. and Christina Lanier, Ph.D. Each episode explores a topic related to treatment courts through conversations with experts in the field. Listeners will gain knowledge and expand their perspectives regarding treatment court work. Dr. DeVall and Dr. Lanier bring a perspective informed by years of experience in the research and practice of treatment courts. It is our hope that Justice To Healing listeners will translate the information presented ...

The addiction treatment industry is facing complex issues, including insurance utilization, parity enforcement, ethics violations, outcomes research gaps, social stigma, and barriers to access along racial and socio-economic lines. At NAATP, we believe that addiction, or substance use disorder, is a bio-psycho-social-spiritual disease that develops and deepens in isolation. Progress in our field, as with recovery itself, can only be achieved through community. That is why we have created All Ears on Addiction, a monthly podcast series, to promote communication, collaboration, and resource ...

On “Rare Insights” we bridge the gap between those living with rare diseases and the biopharmaceutical industry. Know Rare amplifies the voices of individuals with rare conditions, providing invaluable perspectives to accelerate therapeutic solutions. Join us as we dive deep into the complexities of rare diseases, exploring real-world insights from passionate industry leaders. Together, we navigate the unknowns and unlock the potential for groundbreaking treatments. Because in this journey, we’re all rare, sharing unique insights and experiences that drive innovation and progress. Our ...

On our show we will share facts, research, experiences, and feelings to better understand how to save lives from addiction. No prevention, intervention, nor treatment approach is 100% effective, and many people die every day. By sharing our knowledge, experience, and hope we can move further forward in overcoming addiction. There are gaps between traditional addiction recovery concepts like the disease model, new technologies that many consumers are unaware of like family-centered addiction recovery, new research findings about brain chemistry of addiction and genetic vulnerabilities of ...

In this inaugural episode of Psychopharm Today, host Dr. Josh Rosenblat sits down with renowned psychiatrist and researcher, Professor Roger McIntyre, to discuss the growing field of psychedelics research and its potential impact on psychiatric treatment. Dr. Rosenblat is psychiatrist, associate professor, and clinician researcher at the University of Toronto. His research focus is clinical trials of novel psychopharmacological interventions for mood disorders and symptoms that do not respond fully to available treatments. His current research includes trials involving Ketamine and Psilocybin....

Listeners can expect to learn about: • The disease burden and underlying pathophysiology of IgA nephropathy, including the role of endothelin and angiotensin in disease progression • The current IgAN treatment landscape • The response to sparsentan, a dual endothelin angiotensin receptor antagonist, in patients with IgA nephropathy in the phase 3 PROTECT trial